| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TXNIP |
| Uniprot No | Q9H3M7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-391aa |
| 氨基酸序列 | MVMFKKIKSF EVVFNDPEKV YGSGEKVAGR VIVEVCEVTR VKAVRILACG VAKVLWMQGS QQCKQTSEYL RYEDTLLLED QPTGENEMVI MRPGNKYEYK FGFELPQGPL GTSFKGKYGC VDYWVKAFLD RPSQPTQETK KNFEVVDLVD VNTPDLMAPV SAKKEKKVSC MFIPDGRVSV SARIDRKGFC EGDEISIHAD FENTCSRIVV PKAAIVARHT YLANGQTKVL TQKLSSVRGN HIISGTCASW RGKSLRVQKI RPSILGCNIL RVEYSLLIYV SVPGSKKVIL DLPLVIGSRS GLSSRTSSMA SRTSSEMSWV DLNIPDTPEA PPCYMDVIPE DHRLESPTTP LLDDMDGSQD SPIFMYAPEF KFMPPPTYTE VDPCILNNNV Q |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TXNIP重组蛋白的3篇参考文献示例(注：文献为虚构示例，实际引用需查询真实数据库)：
---
1. **文献名称**：*Recombinant TXNIP suppresses ROS production and ameliorates diabetic cardiomyopathy in mice*
**作者**：Wang X, et al.
**摘要**：研究通过重组TXNIP蛋白干预糖尿病小鼠模型，证明其通过抑制活性氧(ROS)生成和调节硫氧还蛋白通路，显著改善心肌纤维化与心功能异常。
2. **文献名称**：*Expression and functional characterization of human TXNIP in a prokaryotic system*
**作者**：Kim S, et al.
**摘要**：报道了一种利用大肠杆菌表达系统高效制备可溶性人源TXNIP重组蛋白的方法，并验证其与硫氧还蛋白的结合活性，为体外机制研究提供工具。
3. **文献名称**：*TXNIP recombinant protein attenuates NLRP3 inflammasome activation in Alzheimer's disease models*
**作者**：Garcia R, et al.
**摘要**：发现重组TXNIP蛋白可通过阻断NLRP3炎症小体信号通路，减少β-淀粉样蛋白诱导的神经炎症反应，提示其治疗神经退行性疾病的潜力。
---
如需真实文献，建议在PubMed或Web of Science中搜索关键词“TXNIP recombinant protein”或“recombinant TXNIP”，并筛选涉及蛋白表达、功能验证或治疗应用的研究。
**Background of TXNIP Recombinant Protein**
TXNIP (Thioredoxin-interacting protein), also known as VDUP1 (Vitamin D3-upregulated protein 1), is a multifunctional protein encoded by the *TXNIP* gene. It belongs to the α-arrestin protein family and plays a critical role in cellular redox regulation by binding to and inhibiting thioredoxin (TRX), a key antioxidant enzyme involved in maintaining oxidative stress balance. TXNIP is implicated in diverse physiological and pathological processes, including glucose metabolism, inflammation, apoptosis, and cellular energy homeostasis.
Recombinant TXNIP protein is engineered through molecular cloning techniques, typically expressed in *E. coli* or mammalian cell systems, to ensure proper folding and post-translational modifications. This recombinant form retains the functional domains required for interacting with TRX and other partners, such as NLRP3 inflammasome components, making it a valuable tool for studying oxidative stress-related pathways.
Research highlights TXNIP's dual role as both a tumor suppressor and a disease promoter, depending on cellular context. In diabetes, TXNIP overexpression in pancreatic β-cells contributes to insulin resistance and apoptosis, linking it to diabetes progression. Conversely, in cancer, TXNIP can suppress tumor growth by modulating glucose uptake and promoting apoptosis, though its downregulation in certain cancers suggests context-dependent roles.
The availability of recombinant TXNIP protein facilitates mechanistic studies, drug screening, and therapeutic development. For example, inhibitors targeting TXNIP-TRX interactions are explored for treating metabolic disorders, while its role in NLRP3 activation positions it as a target for anti-inflammatory therapies. Overall, TXNIP recombinant protein serves as a pivotal reagent in dissecting redox biology and its implications in chronic diseases.
×
